Rhythm Pharmaceuticals, Inc. (RYTM)

Market Cap	3.90B
Revenue (ttm)	130.13M
Net Income (ttm)	-264.57M
Shares Out	63.22M
EPS (ttm)	-4.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	628,864
Open	61.42
Previous Close	61.34
Day's Range	60.98 - 61.90
52-Week Range	35.17 - 68.58
Beta	2.32
Analysts	Strong Buy
Price Target	74.92 (+21.53%)
Earnings Date	May 6, 2025

About RYTM

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 de...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 5, 2017
• Employees: 283
• Stock Exchange: NASDAQ
• Ticker Symbol: RYTM
• Website: https://rhythmtx.com

Financial Performance

In 2024, Rhythm Pharmaceuticals's revenue was $130.13 million, an increase of 68.06% compared to the previous year's $77.43 million. Losses were -$264.57 million, 43.3% more than in 2023.

Analyst Forecast

According to 12 analysts, the average rating for RYTM stock is "Strong Buy." The 12-month stock price forecast is $74.92, which is an increase of 21.53% from the latest price.

Price Target

$74.92

(21.53% upside)

Analyst Consensus: Strong Buy